Extended Data Table 5 Time to surgery

From: Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial

  1. Time from enrollment to surgery (in days) is reported. N, mean, minimum, median, maximum, standard deviation (Std), and the 25th and 75th percentiles are shown.
Back to article page